Evotec/Pfizer initiate Phase I trial of VR1 antagonist « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
August 2008

M T W T F S S

« Jul Sep »

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30 31

Evotec/Pfizer initiate Phase I trial of VR1 antagonist

Posted on August 1, 2008 by crimsoncanary

Evotec AG have announced the initiation of a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist in collaboration with Pfizer

Filed under: Uncategorized | Tagged: antagonist, Evotec, Pfizer, phase I, TRPV1, Vanilloid, vanilloid 1

« Alexza initiate 2nd phase III trial of AZ-004 in schizophrenia/bipolar disorder University of Texas publsihes series for Cannabinoid CB2 agonists »

Leave a Reply